Pages that link to "Q77933570"
Jump to navigation
Jump to search
The following pages link to Three distinct D-amino acid substitutions confer potent antiangiogenic activity on an inactive peptide derived from a thrombospondin-1 type 1 repeat (Q77933570):
Displaying 50 items.
- Histidine-rich glycoprotein inhibits the antiangiogenic effect of thrombospondin-1 (Q24290677) (← links)
- CD36-mediated activation of endothelial cell apoptosis by an N-terminal recombinant fragment of thrombospondin-2 inhibits breast cancer growth and metastasis in vivo (Q24296427) (← links)
- Thrombospondin-1 inhibits nitric oxide signaling via CD36 by inhibiting myristic acid uptake (Q24302047) (← links)
- Thrombospondin-1-induced apoptosis of brain microvascular endothelial cells can be mediated by TNF-R1 (Q24336644) (← links)
- CD36: implications in cardiovascular disease (Q24678338) (← links)
- Crystal structure of the TSP-1 type 1 repeats (Q27639866) (← links)
- Extracellular Matrix, a Hard Player in Angiogenesis (Q28072886) (← links)
- Determination of the CD148-Interacting Region in Thrombospondin-1 (Q28551843) (← links)
- Thrombospondin-1 is a transcriptional repression target of PRMT6. (Q32884548) (← links)
- The role of platelets in tumour growth (Q33803558) (← links)
- Target molecules for anti-angiogenic therapy: from basic research to clinical trials (Q33912018) (← links)
- The functions of thrombospondin-1 and-2. (Q34026331) (← links)
- The cell biology of thrombospondin-1. (Q34096193) (← links)
- Lack of thrombospondin 1 and exacerbation of choroidal neovascularization (Q34122564) (← links)
- Anti-angiogenic treatment strategies for malignant brain tumors (Q34178846) (← links)
- A novel antiangiogenic peptide derived from hepatocyte growth factor inhibits neovascularization in vitro and in vivo (Q34208338) (← links)
- Valproic acid decreases urothelial cancer cell proliferation and induces thrombospondin-1 expression (Q34381913) (← links)
- Thrombospondin-1 as an endogenous inhibitor of angiogenesis and tumor growth. (Q34633187) (← links)
- Treatment of experimental brain tumors with trombospondin-1 derived peptides: an in vivo imaging study (Q34786175) (← links)
- Combined therapy with thrombospondin-1 type I repeats (3TSR) and chemotherapy induces regression and significantly improves survival in a preclinical model of advanced stage epithelial ovarian cancer. (Q35039333) (← links)
- Anti-angiogenic peptides for cancer therapeutics (Q35043016) (← links)
- Expression of the type-1 repeats of thrombospondin-1 inhibits tumor growth through activation of transforming growth factor-beta (Q35102957) (← links)
- Thrombospondins 1 and 2 function as inhibitors of angiogenesis (Q35114389) (← links)
- Antitumor Efficacy of a Thrombospondin 1 Mimetic CovX-Body (Q35116833) (← links)
- The thrombospondins. (Q35230013) (← links)
- PTEN controls tumor-induced angiogenesis (Q35282160) (← links)
- Molecular basis for the regulation of angiogenesis by thrombospondin-1 and -2. (Q35902676) (← links)
- Suppression of Thrombospondin-1 Expression During Uveal Melanoma Progression and Its Potential Therapeutic Utility (Q36054784) (← links)
- ABT-510 induces tumor cell apoptosis and inhibits ovarian tumor growth in an orthotopic, syngeneic model of epithelial ovarian cancer (Q36060215) (← links)
- Identification of TAX2 peptide as a new unpredicted anti-cancer agent. (Q36228487) (← links)
- Cyclic thrombospondin-1 mimetics: grafting of a thrombospondin sequence into circular disulfide-rich frameworks to inhibit endothelial cell migration (Q36321375) (← links)
- Inhibition of endothelial cell migration by thrombospondin-1 type-1 repeats is mediated by beta1 integrins (Q36321428) (← links)
- Thrombospondins in the transition from myocardial infarction to heart failure. (Q36479630) (← links)
- Differential effects of ABT-510 and a CD36-binding peptide derived from the type 1 repeats of thrombospondin-1 on fatty acid uptake, nitric oxide signaling, and caspase activation in vascular cells. (Q36496361) (← links)
- A phase I study of ABT-510 plus bevacizumab in advanced solid tumors (Q36977417) (← links)
- Thrombospondins in cancer (Q37056249) (← links)
- The effect of thrombospondin-1 on breast cancer metastasis (Q37074568) (← links)
- Biological effects of eukaryotic recombinant plasmid pReceiver-M61-BAI-1 transfection on T24 cells and HUVECs (Q37083028) (← links)
- Thrombospondin and apoptosis: molecular mechanisms and use for design of complementation treatments (Q37294120) (← links)
- Analysis of molecular mechanisms and anti-tumoural effects of zoledronic acid in breast cancer cells. (Q37294934) (← links)
- Anti-cancer therapies that utilize cell penetrating peptides. (Q37644518) (← links)
- Targeting tumor angiogenesis with TSP-1-based compounds: rational design of antiangiogenic mimetics of endogenous inhibitors (Q37840948) (← links)
- Therapies using anti-angiogenic peptide mimetics of thrombospondin-1 (Q37963916) (← links)
- Thrombospondin-1 as a Paradigm for the Development of Antiangiogenic Agents Endowed with Multiple Mechanisms of Action. (Q38974266) (← links)
- Thrombospondins: A Role in Cardiovascular Disease (Q39438819) (← links)
- Structure-activity relationships of the human prothrombin kringle-2 peptide derivative NSA9: anti-proliferative activity and cellular internalization (Q40334510) (← links)
- Thrombospondin-1 modulates vascular endothelial growth factor activity at the receptor level (Q42560909) (← links)
- Peptides derived from type I thrombospondin repeat-containing proteins of the CCN family inhibit proliferation and migration of endothelial cells (Q42750998) (← links)
- ABT-510 is an effective chemopreventive agent in the mouse 4-nitroquinoline 1-oxide model of oral carcinogenesis (Q43104986) (← links)
- A phase 1 trial of ABT-510 concurrent with standard chemoradiation for patients with newly diagnosed glioblastoma. (Q43138122) (← links)